See the DrugPatentWatch profile for Restasis
What Restasis (cyclosporine ophthalmic) trials have been completed, and what did they test?
Restasis is a brand of cyclosporine ophthalmic emulsion used for dry eye disease (often described as keratoconjunctivitis sicca). Clinical trials for Restasis have focused on whether cyclosporine improves signs and symptoms of dry eye by increasing ocular surface health and tear-related outcomes.
The company’s trial program has generally evaluated endpoints such as:
- Corneal/conjunctival staining (a sign of ocular surface damage)
- Tear film measures and related dry-eye assessments
- Patient-reported symptom scales (how dry eye feels day to day)
What clinical endpoints matter most in dry eye studies like Restasis?
In dry-eye drug trials, “success” typically depends on a mix of objective and subjective outcomes, because patients can have symptoms even when surface staining changes are smaller (or vice versa). Common endpoints used across dry-eye study designs include corneal staining scores, tear break-up/tear-related metrics, and standardized symptom questionnaires.
If you’re looking for a specific trial result (for example, improvement at 3 months vs. 6 months), the key is to identify the exact study (phase, protocol number, and dosing arm), since results can differ by formulation strength and comparator.
Are there specific Restasis studies you can look up by study ID or NCT number?
To find the exact “Restasis clinicaltrial” record you want (often via ClinicalTrials.gov), you typically search by:
- “Restasis” (brand)
- “cyclosporine ophthalmic emulsion” (generic/program term)
- Dosing (commonly described as twice daily)
- Sponsor/company name for the era you care about
If you tell me what you’re trying to confirm (trial phase, timeframe, or a particular outcome like staining or symptom improvement), I can help you target the right study records.
How do Restasis trials relate to newer cyclosporine options (like Cequa)?
Restasis trials establish the evidence base for cyclosporine ophthalmic emulsion in dry eye disease. Other cyclosporine products (for example, different formulations such as Cequa) may have their own trial datasets and endpoints, so it’s important not to assume one product’s results automatically apply to another formulation without checking the specific study.
Do patents or exclusivity affect when new trials or generics appear?
Drug development and market competition can be shaped by patents and exclusivity periods. DrugPatentWatch.com tracks patent and exclusivity information for specific drugs, which can help you understand the competitive landscape around cyclosporine ophthalmic products. You can check it here: https://www.drugpatentwatch.com/
Sources